阅读说明：本技术 半枝莲提取物的新用途 (New application of sculellaria barbata extract ) 是由 徐闯 崔一喆 常仁旭 于 2019-12-04 设计创作，主要内容包括：本发明涉及一种半枝莲提取物在制备治疗非酒精性脂肪肝的药物中的应用。本发明还提供了半枝莲提取物的制备方法。本发明中的半枝莲提取物对非酒精性脂肪肝小鼠体内脂沉积具有抑制作用,并能够显著改善非酒精性脂肪小鼠炎性反应,半枝莲提取物对高脂饮食诱导的小鼠非酒精性脂肪肝具有预防作用。(The invention relates to an application of a barbed skullcap herb extract in preparing a medicament for treating non-alcoholic fatty liver disease. The invention also provides a preparation method of the sculellaria barbata extract. The herba scutellariae barbatae extract disclosed by the invention has an inhibiting effect on lipid deposition in a mouse with non-alcoholic fatty liver, can obviously improve inflammatory reaction of the mouse with non-alcoholic fatty liver, and has a prevention effect on the mouse with non-alcoholic fatty liver induced by high-fat diet.)

1. An application of herba Scutellariae Barbatae extract in preparing medicine for treating non-alcoholic fatty liver disease is provided.

2. Use according to claim 1, characterized in that: the preparation method of the sculellaria barbata extract comprises the following steps: adding distilled water into the sculellaria barbata decoction pieces according to the weight ratio of 1:10, soaking overnight, decocting, extracting, heating to slightly boil, keeping slightly boiling for 50min, filtering to obtain a middle liquid medicine, adding distilled water into the residual medicine dregs according to the weight ratio of 1:8, keeping slightly boiling for 30min, and filtering to obtain a middle liquid medicine; and finally, combining the two liquid medicines, heating and concentrating until the concentration of the crude drug is 1.5 g/mL to obtain the traditional Chinese medicine.

Technical Field

The invention belongs to the field of traditional Chinese medicines, and relates to a new application of a sculellaria barbata extract.

Background

Non-alcoholic fatty liver disease (NAFLD) is one of the liver diseases commonly seen worldwide and has become the most important public health problem worldwide in the 21 st century. The pathogenesis of NAFLD is more complex, and the theory acknowledged by people at present is the theory of 'secondary attack'; the primary hit is mainly fat deposition caused by abnormal lipid metabolism of the body due to various reasons, and the secondary hit is mainly pathological changes such as inflammation, necrosis and the like of fatty degeneration liver cells caused by various reaction ways, and finally fatty liver fibrosis and fatty liver cirrhosis can be formed.

Most current methods of treating fatty liver reduce metabolic syndrome by losing weight and increasing insulin sensitivity. Currently, insulin sensitizers, antioxidants and lipid lowering agents are the most commonly used three drugs, but they cause side effects such as weight gain and increased mortality, respectively. Rosiglitazone has long been considered as an effective drug for the treatment of non-alcoholic fatty liver disease by improving steatosis and transaminase levels, but subsequent studies have shown that rosiglitazone is cardiovascular-hazardous and therefore this drug is banned in many other countries. Statins are cholesterol-lowering drugs and also are common therapeutic drugs for non-alcoholic fatty liver diseases, which can treat non-alcoholic fatty liver by inhibiting steatosis and steatohepatitis. However, some studies have shown that chronic use of statins may lead to diseases such as acute renal failure. In short, the currently used drugs have certain side effects. Traditional Chinese medicine gradually enters the visual field of researchers due to the advantage of small side effects. Through long-term practice and exploration of the traditional Chinese medicines, various traditional Chinese medicine compounds and classical formulas for treating and preventing the fatty liver are widely applied. The traditional Chinese medicine has unique advantages in the aspect of treating the non-alcoholic fatty liver, so that the traditional Chinese medicine which has wide development sources, safety, reliability, obvious effect and no toxic or side effect is gradually concerned by people as a substitute medicine.

Scutellaria barbata is a dry whole herb of Scutellaria barbata D.Don belonging to Scutellaria of Labiatae, and is recorded in Jiang appliance, Yao Jing Shi Yi (medical mirror Yi of Yi-Shi-Yi), and herba mesonae chinensis, which is used for treating sore throat, damp-heat diarrhea, traumatic injury and other symptoms, and Scutellaria barbata is mainly produced in Jiangxi, Jiangsu, Guangdong, Fujian and other places in China and is recorded in 2015 edition of Chinese pharmacopoeia. Scutellaria barbata contains carthamin (carthamidin), kainic acid (scutellel-arin), stearic acid (stearic acid), alkaloid polysaccharide and other effective components. The crude extract and active component of herba Scutellariae Barbatae have long been used as medicine for treating liver diseases such as hepatitis and hepatocellular carcinoma, and can also improve inflammatory reaction and oxidative stress of certain cells. The sculellaria barbata extract also has good antioxidant activity, and can inhibit liver injury by regulating liver oxidative stress level, thereby protecting liver. Modern pharmacological activity research shows that the barbed skullcap herb also has good anti-tumor activity. At present, no report related to the application of the sculellaria barbata or the extract thereof to the nonalcoholic fatty liver disease is found.

Disclosure of Invention

The invention aims to provide a new application of a barbat skullcap extract, and solves the problems that the existing medicines for treating the non-alcoholic fatty liver disease are western medicines generally and have great side effects.

The second purpose of the invention is to provide a preparation method of the sculellaria barbata extract.

The invention is realized by the following technical scheme:

an application of a barbed skullcap herb extract in preparing a medicament for treating non-alcoholic fatty liver disease.

Secondly, the preparation method of the sculellaria barbata extract comprises the following steps: soaking herba Scutellariae Barbatae decoction pieces in 10 times of distilled water overnight, decocting, heating to slightly boil, maintaining slightly boiling for 50min, filtering to obtain a Chinese medicinal liquid, adding 8 times of distilled water into the residue, maintaining slightly boiling for 30min, and filtering to obtain a Chinese medicinal liquid; and finally, combining the two liquid medicines, heating and concentrating until the concentration of the crude drug is 1.5 g/mL to obtain the traditional Chinese medicine.

Adopt above-mentioned technical scheme's positive effect: the herba scutellariae barbatae extract disclosed by the invention has an inhibiting effect on lipid deposition in a mouse with non-alcoholic fatty liver, can obviously improve inflammatory reaction of the mouse with non-alcoholic fatty liver, and has a prevention effect on the mouse with non-alcoholic fatty liver induced by high-fat diet.

Detailed Description

The technical solution of the present invention is further described with reference to the following specific examples, which should not be construed as limiting the present invention: